



DERMACYN™ WOUND CARE FROM OCULUS INNOVATIVE SCIENCES RECEIVES CE MARK APPROVAL FOR TREATING ACUTE AND CHRONIC WOUNDS IN EUROPE
Based on innovative Microcyn™ technology, Dermacyn™ Wound Care meets requirements of European Medical Devices Directive

SITTARD, THE NETHERLANDS--(November 24, 2004)— Oculus Innovative Sciences Netherlands B.V., a wholly owned subsidiary of Oculus Innovative Sciences of the United States, today announced that the company's newly developed wound treatment product, Dermacyn™ Wound Care, has received CE approval under the European Medical Devices Directive 93/42/EEC. The super-oxidized solution, with revolutionary Microcyn™ technology, can be broadly applied within the comprehensive treatment of acute and chronic wounds (e.g. diabetic foot ulcers and burns). Dermacyn™ Wound Care provides for unparalleled safety for patient, medical practitioner and the environment.

The Netherlands facility was recently certified according to the ISO 13485:2003 quality and management system standard, and is now ramping to begin production of the Dermacyn™ Wound Care as well as other Microcyn™-based products as regulatory approvals are secured. Distribution will take place via a regionally segmented distributor network, which is currently being deployed throughout the European territory. The Dermacyn™ Wound Care CE approval is also crucial in the opening of other international markets such as Latin America, Africa and the eastern markets.

About Oculus

Oculus Innovative Sciences Netherlands B.V., a wholly owned subsidiary of Oculus Innovative Sciences was founded at the end of 2003. This European entity directs the marketing, manufacturing and distribution of Microcyn™-based products in Europe, Africa and Eastern markets. The facility is located in Sittard, in the southeastern part of the Netherlands; strategically located for access to these markets. The Sittard region provides an excellent business infrastructure and a regional government with a genuine appreciation of life sciences technologies. Oculus Innovative Sciences, Inc., headquartered in Petaluma, California, is pioneering innovative life sciences and disruptive technologies that globally re-define the disinfectant and antiseptic markets. With a primary focus on anti-infective and wound management technologies, the company has employees and operations in Mexico, Europe and the U.S. In addition to The Netherlands operation, Oculus Technologies of Mexico, S.A. de C.V. is also a wholly owned subsidiary of the company. For more information www.oculusis.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements relate to, among other things, plans and timing for the introduction of our products, statements about future market conditions, supply and demand conditions, revenues, gross margins, operating expenses, profits and other expectations, intentions and plans contained in this press release that are not historical fact. Our expectations as expressed in this press release depend upon our ability to develop, manufacture and supply products that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in the health sciences market. In light of the many risks and uncertainties surrounding this market, you should understand that we cannot assure you that the forward-looking statements contained in this press release will be realized.